Español 
English
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Artículos Relacionados
-
UDIBI
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection....
-
-
UDIBI
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. VER MÁS
-
UDIBI
Fecha de publicación: Marzo 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio Ver más
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. VER MÁS
